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Diabetic retinopathy (DR) is one of the most common retinal diseases world-wide. It has a complex pathology that involves the 
vasculature of the inner retina and breakdown of the blood-retinal barrier. Extensive research has determined that DR is not 
only a vascular disease but also has a neurodegenerative component and that essentially all types of cells in the retina are af-
fected, leading to chronic loss of visual function. A great deal of work using animal models of DR has established the loss of 
neurons and pathology of other cell types, including supporting glial cells. There has also been an increased emphasis on 
measuring retinal function in the models, as well as further validation and extension of the animal studies by clinical and 
translational research. This article will attempt to summarize the more recent developments in research towards understanding 
the complexities of retinal neurodegeneration and functional vision loss in DR. 
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Over the last 20 years the concept that neurodegeneration 
plays a part in diabetic retinopathy (DR) has become widely 
accepted. A central part of the neurodegeneration hypothe-
sis was that death of neurons was the primary cause of vi-
sion loss in diabetic retinopathy (DR). This was a simplistic 
approach towards a complex disease, and more recent evi-
dence suggests that other processes may contribute to re-
duced neuronal function and vision loss before cell death 
occurs; alongside changes in the regulatory mechanisms of 
the retinal vasculature. Neurodegeneration is usually char-
acterized as being chronic in nature, resulting in a cumula-
tive loss of neurons, photoreceptors and glial cells, as well 
as associated pathologies in the vasculature. Evidence from 
basic research using animal models of DR supports the no-
tion that apoptosis of the retinal tissue is elevated by diabe-
tes, leading to a loss of different cell types as well as a thin-
ning of retinal layers. The observations from animal models 
have now been corroborated by clinical evidence using in 
vivo imaging techniques as well as by histological analysis 
of postmortem specimens. But there is also evidence that 
neurodegeneration is a process that involves more than the 
premature death of neurons, and is likely to include bio-
chemical and morphological changes within neurons and 
their supporting glial cells. It may be that the functional ab-
normalities that are well documented to occur in DR are due 
to earlier alterations in the neural tissue and may precede the 
ultimate elimination of neurons by apoptosis or other forms 
of cell death. This review will consider some of the more 
recent data on retinal disease in diabetes, including neuro-
degeneration and functional deficits that lead to vision loss.  
1  Diabetes induces apoptosis and cell loss in the 
retina 
During the course of research on DR there have been many  
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histological studies to examine its complex pathology. Early 
studies characterized the vascular lesions that were detected 
in post mortem specimens and fundus examination [35]. 
DR is still usually diagnosed by visual identification of a 
variety of vascular lesions such as microaneurysms and li-
pid deposits during the fundus exam, and include the func-
tional breakdown of the blood retinal barrier leading to 
macular edema [6]. But early pathology studies also identi-
fied features of cell death and degeneration in retinal tissue 
from humans with diabetes [7,8]. Since degenerative fea-
tures in neural tissue could not be visually detected during 
the fundus exam they did not contribute to characterization 
or diagnosis of the disease. Further animal studies demon-
strated that experimental diabetes increased apoptotic cell 
death in the vasculature, using the trypsin digest technique 
to isolate the vascular network and then identify apoptotic 
cells by dUTP nick end labeling (TUNEL) [9]. Another 
histological study examined the entire neural retina as a 
flat-mount specimen, also stained by TUNEL [10]. This 
later approach enabled quantification of the total number of 
TUNEL-positive nuclei in each rat retina. The data showed 
that there were significantly more apoptotic cells in the ret-
inas of diabetic rats compared to age-matched controls, 
even in rats that had been diabetic for only one month. The 
actual number of TUNEL-positive cells in each retina was 
quite small, however, ranging between 60 and 120 cells in a 
standardized area of 0.5 cm2, but the number of apoptotic 
cells remained similar in groups of  rats that were diabetic 
for 1, 3, 6 and 12 months. These data suggested that while 
diabetes increased the rate of cell death in the retina, it was 
the result of a chronic degenerative process that began 
within weeks after the onset of hyperglycemia. This study 
also reported that the thickness of the inner plexiform and 
inner nuclear layers of retinas from rats that were diabetic 
for 7.5 months were also significantly reduced (by 22% and 
14%, respectively), again suggesting that the chronic loss of 
cells resulted in degeneration of neurons in the inner layers 
of the retina. The data also showed a significant reduction in 
the number of retinal ganglion cell bodies.  
Other studies confirmed the increase in apoptosis using 
TUNEL labeling on whole retinas. It was shown that 
chronically elevated intraocular pressure augmented the 
diabetes-induced TUNEL-positive cell count [11]. The in-
crease in TUNEL-positive cells, loss of retinal ganglion 
cells, and thinning of the inner retina were confirmed in 
streptozotocin-diabetic mice after 14 weeks of hyperglyce-
mia [12], as well as the Ins2Akita mouse, which is a sponta-
neously diabetic model [13], and in the KKAY mouse, 
which is thought to model Type II diabetes [14].   
There has been some degree of variation in the results of 
studies on retinal apoptosis in animal models of diabetes. 
Some cases report a more dramatic increase in apoptosis, 
and one study reported a dramatic loss of the photoreceptors 
after 24 weeks of streptozotocin-diabetes [15], but this re-
sult has not been confirmed and is unlikely to model the 
clinical condition. In contrast, a study on diabetic mice 
yielded negative findings on apoptosis and loss of neurons 
[16], but for the most part the consensus appears to be that 
experimental diabetes in rodents leads to neuronal apoptosis, 
loss of retinal ganglion cells and reduction in the thickness 
of the inner retina [17,18].  
2  The retinal cell death involves several types 
of neurons 
Immunohistochemical work on retinas from diabetic animal 
models extended the concept that many of the cells under-
going apoptosis were subtypes of neurons, including retinal 
ganglion cells and amacrine cells. Immunohistochemistry 
was performed for CM-1, a marker for the activated form of 
caspase-3, which only appears in cells undergoing apoptosis. 
The study revealed a similar magnitude increase in CM-1 
positive cells compared to that measured by TUNEL [1]. 
Many of the CM-1 positive cells appeared spatially distinct 
from blood vessels, which were identified by immunoreac-
tivity for a vascular basement membrane protein called 
agrin, which is abundant in the retinal vasculature [19]. 
These data suggested that CM-1 positive cells were more 
likely to be neurons or glial cells undergoing apoptosis, ra-
ther than vascular cells (Figure 1). The CM-1 signal was 
colocalized with markers such as choline acetyl transferase 
and tyrosine hydroxylase in some cells, indicating choliner-
gic and dopaminergic amacrine cells; as well as NeuN, a 
ubiquitous marker of neurons. This study also found that the 
number of cholinergic and dopaminergic amacrine cells was 
depleted (by 20% and 16%, respectively) in diabetic 
Ins2Akita mice after 6 months of hyperglycemia. An im-
munohistochemistry study on human postmortem tissue also 
identified caspase-3, Fas ligand and Bcl-2 in the nerve fiber 
layer and retinal ganglion cells, confirming that the loss of 
specific neurons by apoptosis also occurs in human diabetes 
[20]. The observed loss of amacrine neurons in diabetic 
rodents was extended recently by a study showing reduced 
levels of retinal dopamine after short durations of hyper-
glycemia in both rats and mice [21], suggesting that there is 
a loss of dopaminergic amacrine cells.  
In summary, it appears that diabetes increases the cell 
death of neurons in the inner retina including retinal gan-
glion cells and both dopaminergic and cholinergic amacrine 
cells, and the cell death has been identified in both animal 
models and in human samples. It is likely that there is also 
accelerated cell death of bipolar cells and some photore-
ceptors. The interdependence and timing of apoptosis in the 
different neuronal populations is unknown and will be dif-
ficult to establish using traditional histological technology 
because of the low frequency of cell death events. Also the 
clinical significance of cell death in DR, especially during 
the early stages of the disease is still debated; however, the 
data now strongly support that apoptosis of retinal neurons  
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Figure 1  Apoptosis of non-vascular cells in retina from STZ-diabetic rats. 
Flat-mount retinas from STZ-diabetic and control rats were labeled for the 
active form caspase-3 (red) and the vascular basement membrane glyco-
protein, agrin (green) and imaged by confocal microscopy. The image 
shows a typical caspase-3 positive cell spatially distinct from agrin immu-
noreactivity on the retinal vasculature, indicating that the cell undergoing 
apoptosis was more likely to have neural rather than vascular origin. Scale 
bar, 50 µm. (Taken from [1]) 
is accelerated by diabetes and the onset of the increase in 
cell death is early in the time course of DR.  
3  In vivo imaging of retinal morphology con-
firms early loss of neurons from the inner retina 
Several recent clinical studies have used in vivo imaging 
techniques to demonstrate thinning of the retinal nerve fiber 
layer in diabetes, often in patients with little or no evidence 
of vascular retinopathy. Scanning laser polarimetry estab-
lished that the thickness of the retinal nerve fiber layer was 
significantly reduced in a small group of type 1 diabetic 
patients without retinopathy or other microvascular compli-
cations [22]. A larger study using the same approach also 
reported thinning in the nerve fiber layer [23]. A more ex-
tensive study on a population of patients with Type II dia-
betes, screened to exclude glaucoma, confirmed the thin-
ning of the retinal nerve fiber layer [24]. These studies 
strongly suggest that there is a gradual loss of retinal gan-
glion cells in diabetic patients. 
Recently there has been a wide expansion of the use of 
optical coherence tomography (OCT) in clinical diagnosis 
and research on retinal diseases. OCT has been used to 
measure subtle changes in the thickness of retinal cell layers 
of people with diabetes, at the very early stages of vascular 
retinopathy. An OCT study of a small number of patients 
with Type II diabetes discovered a significant thinning of 
the nerve fiber layer in the superior quadrants of the retina 
[25]. A further OCT study measured the pericentral retinal 
thickness of patients with Type I diabetes compared to 
healthy controls. The results revealed a statistically signifi-
cant retinal thinning of the pericentral area around the fovea 
in diabetic patients with minimal DR, compared to the 
healthy control group [26]. While the retinal thickness of 
the diabetic patients was only about 5% less than that of the 
healthy subjects, the results indicated a potential early loss 
of axonal tissue in an important region of the macula, pre-
sumably indicating a degeneration affecting retinal ganglion 
cells. A study of a mixed population of Type I and Type II 
diabetic patients showed that the thinning of the nerve fiber 
layer was correlated with fasting blood glucose levels [27]. 
Again it is important to note that the selected population had 
only pre-clinical retinopathy, suggesting that these degener-
ative changes could be detected at an earlier time point than 
major vascular lesions. A similar but higher resolution study 
on diabetic patients who also had minimal retinopathy 
found a differential reduction in the thickness of the com-
bined ganglion cell and inner plexiform layer (by 2.7 µm), 
and a smaller loss of the inner nuclear layer compared to 
healthy age-matched controls [28]. The reductions were 
again limited to the pericentral region of the macula, while 
more peripheral regions of retina were not altered. A follow 
up study by the same investigators reported even greater 
loss of tissue thickness in the pericentral ganglion cell layer 
(5.1 µm) and also a loss in the peripheral macula nerve fiber 
layer (3.7 µm) of patients with Type I diabetes and minimal 
vascular retinopathy [29]. This study also found a signifi-
cant correlation between ganglion cell layer thickness and 
the duration of diabetes. The same research group also es-
tablished that there were similar changes in retinal thickness 
in a group of Type II diabetic patients [30]. A more recent 
study of patients with no clinically detectible macular ede-
ma again reported a significant reduction in the thickness of 
the retinal nerve fiber layer in patients with diabetes, while 
there was also a significant increase in the thickness of the 
inner plexiform and nuclear layers [31]. The authors sug-
gested that the unprecedented increase in thickness of the 
inner retina layers may have been due to Müller cell in-
flammation and swelling, rather than edema, which had not 
been detected during fundus examination. It should also be 
noted that two OCT studies identified sex differences in the 
macular thickness and nerve fiber layer in patients with di-
abetes, so future clinical studies using this approach may be 
required to differentiate between data from males and fe-
males [32,33]. 
The reduction in retina thickness measured by OCT is 
relatively small. But this small loss of inner retina tissue 
may have clinical relevance because some studies have 
demonstrated correlations with functional measures of vi-
sion. One study showed that macular and foveal thickness 
was negatively correlated with duration of diabetes [34], 
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suggesting that the loss of thickness is progressive, and this 
was confirmed more recently [35]. Thinning of the nerve 
fiber layer was also detected in adolescents with Type II 
diabetes, along with reductions in the electroretinogram and 
venular dilation, showing that the structural changes in reti-
nal thickness are accompanied by loss of neural and vascu-
lar function [36]. Another study found that the ganglion cell 
layer thickness was a significant predictor of decreased vis-
ual function measured by the Rarebit perimetry and fovea 
test, which can be used to detect subtle defects in function 
[37,38]. 
There has been a rapid increase in OCT usage in clinical 
research, which has validated the observations of inner reti-
na degeneration in the diabetic animal models. Reductions 
in the thickness of the nerve fiber layer are most likely to 
indicate a reduced abundance of retinal ganglion cell axons, 
and presumably a loss of the cell bodies and dendrites. This 
deficit is likely to limit the ability to transmit visual infor-
mation to the brain and compromise the information pro-
cessing capacity of the inner retina. In most studies the 
nerve fiber layer loss was apparent in a population of pa-
tients that did not have macular edema, suggesting that sig-
nificant neural degeneration occurred before a clinically 
apparent loss of vascular barrier function.  
4  OCT imaging identifies retinal thickness 
changes in animal models of diabetes 
There have been fewer studies using OCT in animal models 
of diabetes compared to the clinical research. But with the 
increase in availability of OCT devices adapted for animals 
it seems likely that this will soon change. Recent data from 
animal models appear to reflect the clinical observations. A 
study of leptin-deficient mice, which are thought to model 
obesity and Type II diabetes, used OCT imaging to show a 
significant reduction in the combined thickness of the nerve 
fiber and inner plexiform layers in mice that were 22 weeks 
old [39]. OCT was also used to establish a significant re-
duction in the thickness of the retinal nerve fiber layer and 
total retinal thickness in Otuska Long-Evans Tokushima 
fatty rats, which also model Type II diabetes [40]. A study 
on the Ins2Akita mouse reported no significant changes in 
retinal thickness using OCT and histology [41], despite ear-
lier histological studies showing a significant reduction in 
the thickness of the inner layers of the Ins2Akita retina [13]. 
A further OCT study, however, reported that Ins2Akita dia-
betic mice did have a progressive thinning of the inner reti-
na which became apparent 3 months after the onset of hy-
perglycemia [42]. It seems likely that the Ins2Akita model 
shows variability between different colonies, and may be a 
less reliable model compared to the streptozotocin-diabetic 
rodents.  
The current consensus appears to be that OCT is a valid 
approach that is sensitive enough to detect reductions in the 
thickness of the inner retina in rodent models of diabetes. 
With the expanding availability of OCT devices adapted for 
rodent imaging it is likely that in vivo measures of retinal 
thinning will become more common in basic and transla-
tional research studies. This will offer a valuable method to 
confirm significant retinal neurodegeneration, and potential 
protection of tissue in translational studies, before the ani-
mals are sacrificed for biochemical or histological analysis.   
5  Degenerative changes in synapses and neuron 
morphology accompany cell death  
In the previous histological studies that measured reductions 
in the thickness of the cell layers of the retina the greatest 
change was in the thickness of the inner plexiform layer, 
accompanied by a smaller reduction in the thickness of the 
inner nuclear layer [10,13]. One explanation for these re-
ductions is that a cumulative loss of amacrine or bipolar 
cells by apoptosis caused the reduction in tissue volume [1], 
but the loss of the inner plexiform layer suggests that there 
was also an accompanying reduction on the volume of den-
drites and synaptic connections. To test this possibility the 
retinas of diabetic rats were labeled by immunofluorescence 
for several protein markers of synapses, including synapto-
physin, which is an abundant presynaptic vesicle protein in 
retina and brain [43]. The results demonstrated that the pro-
tein content of synaptophysin and several other synaptic 
proteins was significantly reduced after 1 and 3 months of 
streptozotocin-induced diabetes in rats. Similar results were 
obtained from the hippocampus a well as retinas of diabetic 
rats, supporting the possibility that diabetes may alter syn-
aptic protein regulation in the brain and other parts of the 
nervous system as well as the retina [44]. The reduction in 
synaptic marker proteins was ameliorated by correcting 
diabetes with insulin if the treatment was initiated after a 
short period of diabetes, but not after a more protracted pe-
riod, suggesting that after longer durations of hyperglyce-
mia the changes in synapse number or synaptic protein con-
tent are irreversible [45]. Blockade of the angiotensin II 
type 1 receptor also protected diabetic rats against the loss 
of synaptophysin [46], as did high doses of lutein in diabetic 
mice, indicating some potential mechanisms [47].  
The significant reductions in synaptic protein content 
occurred soon after the onset of diabetes and cannot be fully 
explained by loss of a small number of neurons, suggesting 
that these degenerative changes may be a precursor to neu-
ronal cell death. Further work used 35S-labeling of explant 
retinas from diabetic and control rats to determine changes 
in the synthesis of synaptophysin [48]. The work suggested 
that abnormal mRNA translation and post-translational 
mannosylation was responsible for the reduced content of 
mature synaptophysin protein. It is possible that early 
dysregulation of synaptophysin synthesis, and possibly oth-
er synaptic proteins, could compromise neurotransmission 
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efficiency leading to an inadequacy in neuron-neuron 
communication required for visual information processing.  
As well as alterations in presynaptic protein regulation, 
diabetes may result in altered neuronal morphology, espe-
cially in retinal ganglion cells. One study labelled retinal 
ganglion cells with DiI delivered by gene gun, and found 
that some retinal ganglion cells of diabetic rats had enlarged 
dendritic fields [49]. Another study used the Ins2Akita mice 
crossed with Thy1-YFP mice, which express yellow fluo-
rescent protein throughout the entire structure of a random 
subset of retinal ganglion cells. Confocal microscopy re-
vealed a number of pathological characteristics in these 
cells including cell body swelling and axonal varicosities 
associated with thinning [2]. There was also a significant 
increase in the density of dendrites in large ON-ganglion 
cells, measured by Scholl analysis (Figure 2). Similar 
pathological features were also described in a small study 
using DiI on postmortem human retinas [50]. The small 
amount of morphological data that is available suggests that 
diabetes leads to changes in the dendrite morphology of 
retinal ganglion cells, possibly as a precursor to cell death, 
and also appears to alter the content of certain synaptic pro-
teins. The data suggest that there is either a reduction in the 
number of synapses or a change in synaptic protein synthe-
sis and turnover, accompanied by alterations in dendrite 
morphology which could be compensatory to reductions in 
synaptic input. It seems likely that these morphological and 
protein regulatory deficits have the potential to compromise 
the functional output of the retina in a way that will influ-
ence vision.  
6  The scotopic threshold response as a measure 
of visual function in diabetes 
One of the more recent trends in diabetic retinopathy re- 
 
 
Figure 2  Retinal ganglion cell morphology in diabetic Ins2Akita mice. 
Ins2Akita and Thy1-YFP mice were crossed to reveal the retinal ganglion 
cell morphology. Whole mount retinas were imaged by confocal micros-
copy to create line maps of individual retinal ganglion cells. A, A typical 
ON-ganglion cell from a wild-type mouse retina. B, ON-ganglion cell from 
a diabetic Ins2Akita/+ mouse showing dendrites with many small terminals 
(arrowheads), and occasional long unbranched dendrites extending beyond 
the normal dendritic arbor (arrow). Scale bar, 50 µm. (Taken from [2]). 
search has been an increased emphasis on functional as-
sessment of vision. Advances in electrophysiological re-
cording equipment have enabled animal research with in-
creased clinical relevance, because the electrophysiological 
response in animals appears to closely reflect the observa-
tions in humans. Subtle alterations in the electroretinogram 
in patients with diabetes have been established for many 
years [5153] and similar changes are found in animal 
models. Typically the b-wave amplitude is reduced while 
the oscillatory potentials are delayed and also reduced in 
amplitude [5458]. While the changes in the ERG wave-
form are well established, it has been difficult to interpret 
what cellular and molecular mechanisms could be responsi-
ble for the deficits because the standard ERG is a composite 
signal derived from the combination of cell populations 
across the entire retina. The scotopic threshold response 
(STR) represents a more selective electrophysiological 
measure compared to the ERG because it is thought to be 
derived from the inner retina and is the result of very low 
intensity light flashes [59,60]. It has both positive and nega-
tive wave components, which are likely derived from retinal 
ganglion cells with a possible contribution from amacrine 
cells in the inner retina because it can be partially abolished 
by optic nerve transection leading to selective ganglion cell 
death [61].  
An early clinical study established that the amplitude of 
the STR was reduced in humans with diabetes [62,63]. 
More recently this observation was confirmed in rats and 
mice with diabetes. The positive STR amplitude was re-
duced by 51% in rats after only 4 weeks of streptozoto-
cin-diabetes, and this deficit preceded significant changes in 
other ERG components [56]. Similarly, diabetic Ins2Akita 
mice had a reduced STR amplitude after 6 weeks of hyper-
glycemia [64]. When non-opioid sigma receptor 1 knockout 
mice were made diabetic, the reduction in the STR was 
greater than that in diabetic wild-type mice, and the diabetic 
knockout mice also had fewer surviving retinal ganglion 
cells, suggesting that the reduced STR is related to acceler-
ated RGC death [65]. A study on rats suggested that the 
reduction in STR ganglion cell function correlated with in-
creases in connective tissue growth factor and the TGFβ 
receptor, rather than gross morphological changes in the 
inner retina and optic nerve [66].  
The STR is generally considered more difficult to meas-
ure than the standard ERG because its amplitude is small 
and is a response to very low intensity stimuli. Measuring 
the STR requires extensive dark adaptation as well as ex-
tensive response averaging. Introduction of modern elec-
trophysiology equipment, however, has made this approach 
more practicable; especially in animals because they can be 
dark adapted over several hours and are anesthetized during 
recording. The ERG has been used extensively to measure 
retinal function in rodent models of diabetes but there are 
opportunities such as the STR and other electrophysiologi-
cal paradigms to reveal mechanistic information about more 
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specific functional deficits in diabetes. 
7  Measurement of visual function using opto-
kinetic behavior in animal models of diabetes 
The introduction of equipment to accurately measure the 
optokinetic response of rodents [67] has enabled measures 
of deficits in spatial frequency threshold and contrast sensi-
tivity in animal models of diabetes. An initial study showed 
that diabetic Long-Evans rats had significant optokinetic 
defects after 4 weeks of hyperglycemia [68]. The visual 
deficits were also identified in the Ins2Akita mouse but ap-
pear to progress at a slower rate compared to rats [6971]. 
The loss of visual function in streptozotocin-diabetic Long- 
Evans rats became significant after 1 month of hyperglyce-
mia and correlated with ERG implicit times, although these 
changes also correlated with lens opacity in animals with 
longer durations of diabetes [58]. Part of the early deficit in 
visual function may, however, be due to loss of dopamine 
signaling, since the reductions in optokinetic behavior and 
ERG were prevented by therapy with L-DOPA [21]. Also, 
diabetic mice with a knock out for aldose reductase did not 
have the visual function deficit [72]. Furthermore, reduction 
of the oxidative stress response through mutation of the 
transcription factor, Nrf2, also worsened the optokinetic 
visual function in diabetic mice, suggesting that super oxide 
production can worsen vision loss in diabetes [73].   
8  Functional changes in neuro-vascular cou-
pling 
Compromised vascular function is synonymous with DR. 
The loss of integrity of the inner blood-retinal barrier is well 
established and the primary cause of macular edema [74]. It 
is thought that this is due in part to dysregulation of the 
vascular endothelial tight junction proteins that are respon-
sible for creating the permeability barrier [75,76]. Recently 
there has been documentation of other functional changes in 
retinal neuro-vascular coupling that may occur early in dia-
betes [77]. One study used a dynamic retinal vessel analyzer 
to measure real-time changes in the caliber of large retinal 
vessels in response to metabolic challenges induced by 
flickering light or hyperoxia. The results indicated that pa-
tients with Type II diabetes had an impaired arterial vasodi-
lator and vasoconstrictor response. The impairment did not 
correlate with blood glucose or insulin levels, suggesting 
that the mechanism was not dependent on the acute diabetic 
state [78]. A further study found similar results in a clinical 
population with pre-diabetes, defined as HbA1C between 
5.7% and 6.5%. The deficit in the pre-diabetic populations 
was similar to that of the diabetic population with HbA1C 
above 6.5%, suggesting that this is an early event in the 
course of DR and could represent a sensitive predictive 
measure [79]. Another recent study suggested that retinal 
neurovascular coupling is influenced by blood glucose be-
cause improving glycemic control with the dipeptidyl pep-
tidase-4 inhibitor, saxagliptin, also improved retinal hemo-
dynamics in patients with Type II diabetes [80]. This early 
change in neurovascular function may also occur in the ab-
sence of detectible changes in electrophysiological function 
measured by multifocal ERG, suggesting that it is inde-
pendent of neuronal deficits [81]. Other data, however, 
show that multifocal ERG deficits can be predictive of the 
appearance of vascular lesions occurring within 23 years 
[82,83]. Neurovascular coupling is the result of a functional 
relationship between vascular and neural cells. Diabetes 
leads to a breakdown in this relationship, causing a failure 
of the vasculature to respond appropriately to the local 
metabolic demand of the neural tissue. While the mecha-
nisms for these deficits are poorly understood, changes in 
neurovascular coupling may represent an early predictor for 
DR.   
9  Conclusion 
DR is a disease with a complex and progressive pathology 
[84]. Early in the progress of the disease there are changes 
in the vascular and neural components of the tissue leading 
to abnormal neurovascular coupling [78,79]. Although it is 
unclear if functional changes in the vasculature are patho-
logical or compensatory, they may represent a method for 
early diagnosis of the disease. There are also subtle but 
measurable deficits in visual function that may become pre-
dictors of disease progression after more research 
[64,8588].   
The underlying mechanisms of retinal neurodegeneration 
in DR are still unclear. It is still not known if the neuropathy 
that is now well established to occur in the retina is associ-
ated with or independent of the development of microvas-
cular disease, but understanding the early alterations in the 
neural component of the retina may offer greater opportuni-
ties for early diagnosis and treatment. The biochemical 
changes that precede cell death are more likely to be re-
versible with pharmacological intervention. Thus the best 
hope for developing the successful preventive medicines of 
the future will be through further research into the early 
mechanisms of retinal degeneration in diabetes. This work 
must include an increasing emphasis on methods to assess 
the early deficits in visual function. Our goal should be to 
develop better methods for early detection of DR as well as 
new preventive therapies.   
The author acknowledges past funding from the Juvenile Diabetes Re-
search Foundation International, the American Diabetes Association, the 
Pennsylvania Lions Sight Conservation and Eye Research Foundation, and 
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